Polymer nanotechnology based approaches in mucosal vaccine delivery: Challenges and opportunities

Biotechnology Advances

Volumn 33, Issue 1, 2015, Pages 64-79

  Sharma, Rajeev ^a   Agrawal, Udita ^a   Mody, Nishi ^a   Vyas, Suresh P ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

Antigen; Mucosal delivery; Mucosal immunization; Nanoparticles; Polymers

Indexed keywords

ANTIGENS; IMMUNIZATION; NANOPARTICLES; NANOTECHNOLOGY; POLYMERS; VACCINES;

DEVELOPMENT AND TESTING; FUTURE PERSPECTIVES; MUCOSAL DELIVERY; MUCOSAL IMMUNE RESPONSE; MUCOSAL IMMUNIZATION; NANO-ARCHITECTURE; POLYMERIC NANOPARTICLES; VACCINATION STRATEGY;

IMMUNE SYSTEM;

ANTIGEN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; NANOTECHNOLOGY; POLYMER; VACCINE;

IMMUNOLOGICAL ADJUVANT; NANOPARTICLE; POLYMER; VACCINE;

ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MUCOSA; MUCOSAL IMMUNITY; NANOTECHNOLOGY; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; IMMUNITY, MUCOSAL; MUCOUS MEMBRANE; NANOPARTICLES; NANOTECHNOLOGY; POLYMERS; VACCINES;

EID: 84922837456     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2014.12.004     Document Type: Review

References (158)

1. Adrienne V.L., James J.M., Wuhbet A., Suh H., Elkhader J., Seidman M.A., et al. Generation of Effector Memory T Cell-Based Mucosal and Systemic Immunity with Pulmonary Nanoparticle Vaccination. Sci Transl Med 2012, 4:138-179.
2. Akagi T., Akashi M. Development of polymeric nanoparticles-based vaccine. Nihon Rinsho 2006, 64(2):279-285.
3. Akagi T., Masanori B., Akashi M. Biodegradable Nanoparticles as Vaccine Adjuvants and Delivery Systems: Regulation of Immune Responses by Nanoparticle-Based Vaccine. Adv Poly Sci 2012, 247:31-64.
4. Almeida A.J., Alpar H.O., Brown M.R. Immune response to nasal delivery of antigenically intact tetanus toxoid associated with poly(L-lactic acid) microspheres in rats, rabbits and guinea-pigs. J Pharm Pharmacol 1993, 45(3):198-203.
5. Andrianov A.K. Polyphosphazenes as Vaccine Adjuvants. Vaccine Adjuvants and Delivery Systems 2006, 355-378. John Wiley & Sons, Inc, Hoboken, NJ, USA.
6. Ayman M.Gebril, Lamprou D.A., Alsaadi M.M., Stimson W.H., Mullen A.B., Ferro V.A. Assessment of the antigen-specific antibody response induced by mucosal administration of a GnRH conjugate entrapped in lipid Nanoparticles. Nanomed Nanotechnol Biol Med 2014, 10.1016/j.nano.2013.12.005.
7. Benoit M.A., Baras B., Gillard J. Preparation and characterization of protein-loaded poly (epsilon-caprolactone) microparticles for oral vaccine delivery. Int J Pharm 1999, 184(1):73-84.
8. Bhavsar M.D., Amiji M.M. Polymeric nano and microparticle technologies for oral gene delivery. Expert Opin Drug Deliv 2007, 4:197-213.
9. Bhavsar M.D., Amiji M.M. Development of novel biodegradable polymeric nanoparticles-in-microsphere formulation for local plasmid DNA delivery in the gastrointestinal tract. AAPS 2007, 9:288-294.
10. Bhavsar M.D., Amiji M.M. Development of novel biodegradable polymeric nanoparticles-in-microsphere formulation for local plasmid DNA delivery in the gastrointestinal tract. AAPS Pharm Sci Tech 2008, 9:288-294.
11. Bhavsar M.D., Amiji M.M. Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease. Gene Ther 2008, 15:1200-1209.
12. Bhavsar M.D., Tiwari S.B., Amiji M.M. Formulation optimization for the nanoparticles-in- microsphere hybrid oral delivery system using factorial design. J Control Release 2006, 110:422-430.
13. Binjawadagi B., Dwivedi V., Manickam C., Ouyang K., Wu Y., Lee L.J., et al. Adjuvanted poly(lactic-co-glycolic) acid nanoparticle-entrapped inactivated porcine reproductive and respiratory syndrome virus vaccine elicits cross-protective immune response in pigs. Int J Nanomedicine 2014, 9(1):679-694.
14. Boudier A., Aubert-Pouessel A., Louis-Plence P., Gérardin C., Jorgensen C., Devoisselle J.M. The control of dendritic cell maturation by pH-sensitive polyion complex micelles. Biomaterials 2009, 30:233-241.
15. Brandtzaeg P. Nature and function of gastrointestinal antigen-presenting cells. Allergy 2001, 56:16-20.
16. Camacho A.I., Irache J.M., de Souza J., Sanchez- Gomez S., Gamazo C. Nanoparticle-based vaccine for mucosal protection against Shigella flexneri in mice. Vaccine 2013, 31(32):3288-3294.
17. Carrillo-Conde B., Schiltz E., Yu J., Chris Minion F., Phillips G.J., Wannemuehler M.J., et al. Encapsulation into amphiphilic polyanhydride microparticles stabilizes Yersinia pestisantigens. Acta Biomater 2010, 6:3110-3119.
18. Cesta M. Normal Structure, Function, and Histology of Mucosa-Associated Lymphoid Tissue. Toxicol Pathol 2006, 34:599-608.
19. Chahine B.G., Bahna S.L. The role of the gut mucosal immunity in the development of tolerance versus development of allergy to food. Curr Opin Allergy Clin Immunol 2010, 10:394-399.
20. Champion J.A., Mitragotri S. Shape induced inhibition of phagocytosis of polymer particles. Pharm Res 2009, 26:244-249.
21. Cu Y., Booth C.J., Saltzman W.M. In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery. J Control Release 2011, 156(2):258-264.
22. Curtis J., Greenberg M., Kester J., Phillips S., Krieger G. Nanotechnology and nanotoxicology: a primer for clinicians. Toxicol Sci 2006, 25:245-260.
23. Czerkinsky C., Holmgren J. Enteric vaccines for the developing world: a challenge for mucosal immunology. Mucosal Immunol 2009, 2:284-287.
24. Czerkinsky C., Holmgren J. Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues. Curr Top Microbiol Immunol 2010, 354:1-18.
25. Danhier F., Ansorena E., Silva J.M., Coco R., Le Breton A., Préat V. PLGA-based nanoparticles: An overview of biomedical applications. J Control Release 2012, 161:505-522.
26. Dea-Ayuela M.A., Rama-Iniguez S., Torrado-Santiago S., Bolas-Fernandez F. Microcapsules formulated in the enteric coating copolymer Eudragit L100 as delivery systems for oral vaccination against infections by gastrointestinal nematode parasites. J Drug Target 2006, 14:567-575.
27. Demento S.L., Cui W., Criscione J.M., Stern E., Tulipan J., Kaech S.M., et al. Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype. Biomaterials 2012, 33(19):4957-4964.
28. Diebold S.S., Cotten M., Koch N., Zenke M. MHC class II presentation of endogenously expressed antigens by transfected dendritic cells. Gene Ther 2001, 8:487-493.
29. Doroud D., Vatanara A., Zahedifard F., Gholami E., Vahabpour R., Rouholamini Najafabadi A., et al. Cationic solid lipid nanoparticles loaded by cysteine proteinase genes as a novel anti-leishmaniasis DNA vaccine delivery system: characterization and in vitro evaluations. J Pharm Sci 2010, 13:320-335.
30. Doroud D., Zahedifard F., Vatanara A., Najafabadi A.R., Rafati S. Cysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against L. major infection in C57BL/6 mice. Parasite Immunol 2011, 33:335-348.
31. Doroud D., Zahedifard F., Vatanara A., Najafabadi A.R., Taslimi Y., Vahabpour R., et al. Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection. J Control Release 2011, 153:154-162.
32. Duncan R., Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm 2011, 8:2101-2141.
33. Durán-Lobato M., Carrillo-Conde B., Khairandish Y., Peppas N.A. Surface-modified P(HEMA-co-MAA) nanogel carriers for oral vaccine delivery: Design, characterization, and in vitro targeting evaluation. Biomacromolecules 2014, 15:2725-2734.
34. Dwivedi V., Manickam C., Binjawadagi B., Renukaradhya G.J. PLGA nanoparticle entrapped killed porcine reproductive and respiratory syndrome virus vaccine helps in viral clearance in pigs. Vet Microbiol 2013, 166(1-2):47-58.
35. Einstein M.H., Schiller J.T., Viscidi R.P., Strickler H.D., Coursaget P., Tan T., et al. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 2009, 9:347-356.
36. Ekici S., Ilgin P., Butun S., Sahiner N. Hyaluronic acid hydrogel particles with tunable charges as potential drug delivery devices. Carbohydr Polym 2011, 84(4):1306-1313.
37. Elechiguerra J.L., Burt J.L., Morones J.R., Camacho-Bragado A., Gao X., Lara H.H., et al. Interaction of silver nanoparticles with HIV-1. J Nanobiotechnol 2005, 3:6.
38. Eng N.F., Garlapati S., Gerdts V., Potter A., Babiuk L.A., Mutwiri G.K. The potential of polyphosphazenes for delivery of vaccine antigens and immunotherapeutic agents. Curr Drug Deliv 2010, 7:13-20.
39. Feng G., Jiang Q., Xia M., Lu Y., Qiu W., Zhao D., et al. Enhanced immune response and protective effects of nano-chitosan-based DNA vaccine encoding T cell epitopes of Esat-6 and FL against Mycobacterium tuberculosis infection. PLoS One 2013, 8:e61135.
40. Fievez V., Plapied L., des Rieux A., Pourcelle V., Freichels H., Wascotte V., et al. Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination. Eur J Pharm Biopharm 2009, 73(1):16-24.
41. Florindo H.F., Pandit S., Gonçalves L.M.D., Alpar H.O., Almeida A.J. New approach on the development of a mucosal vaccine against strangles: Systemic and mucosal immune responses in a mouse model. Vaccine 2009, 27(8):1230-1241.
42. Florindo H.F., Pandit S., Lacerda L., Gonçalves L.M.D., Alpar H.O., Almeida A.J. The enhancement of the immune response against S. equi antigens through the intranasal administration of poly-e{open}-caprolactone-based nanoparticles. Biomaterials 2009, 30(5):879-891.
43. Florindo H.F., Pandit S., Gonçalves L.M., Alpar H.O., Almeida A.J. Surface modified polymeric nanoparticles for immunisation against equine strangles. Int J Pharm 2010, 390(1):25-31.
44. Foged C., Brodin B., Frokjaer S., Sundblad A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm 2005, 298:315-322.
45. Garinot M., Fiévez V., Pourcelle V., Stoffelbach F., des Rieux A., Plapied L., et al. PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J Control Release 2007, 120(3):195-204.
46. Gebert A., Steinmetz I., Fassbender S., Wendlandt K.H. Antigen transport into Peyer's patches: increased uptake by constant numbers of M Cells. Am J Pathol 2004, 164:65-72.
47. Gherardi R.K., Coquet M., Cherin P., Belec L., Moretto P., Dreyfus P.A., et al. Macrophagic myofasciitis lesions assess longterm persistence of vaccine-derived aluminium hydroxide in muscle. Brain 2001, 124:1821-1831.
48. Giuliano E.A., Moore C.P., Phillips T.E. Morphological evidence of M cells in healthy canine conjunctiva-associated lymphoid tissue. Graefes Arch Clin Exp Ophthalmol 2002, 240:220-226.
49. Goodman C.M., McCusker C.D., Yilmaz T., Rotello V.M. Toxicity of gold nanoparticles functionalized with cationic and anionic side chains. Bioconjug Chem 2004, 15:897-900.
50. Gupta N.K., Tomar P., Sharma V., Dixit V.K. Development and characterization of chitosan coated poly-(e{open}-caprolactone) nanoparticulate system for effective immunization against influenza. Vaccine 2011, 29(48):9026-9037.
51. Gupta P.N., Mahor S., Rawat A., Khatri K., Goyal A., Vyas S.P. Lectin anchored stabilized biodegradable nanoparticles for oral immunization: Development and in vitro evaluation. Int J Pharm 2006, 318:163-173.
52. Gupta R.K., Singh M., O'Hagan D.T. Poly (lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines. Adv Drug Deliv Rev 1998, 32:225-246.
53. Gutierro I., Hernández R.M., Igartua M., Gascón A.R., Pedraz J.L. Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine 2002, 21:67-77.
54. Haas J., Kumar M.N.R., Borchard G., Bakowsky U., Lehr C.M. Preparation and char-acterization of chitosan and trimethyl-chitosan-modified poly(€-caprolactone) nanoparticles as DNA carriers. AAPS Pharm Sci Tech 2005, 6:E22-E30.
55. Hanson J.A., Chang C.B., Graves S.M., Li Z., Mason T.G., Deming T.J. Nanoscale double emulsions stabilized by single-component block copolypeptides. Nature 2008, 455:85-88.
56. Harde H., Agrawal A.K., Jain S. Development of stabilized glucomannosylated chitosan nanoparticles using tandem crosslinking method for oral vaccine delivery. Nanomedicine 2014, 10.2217/nnm.13.225.
57. Haughney S.L., Ross K.A., Boggiatto P.M., Wannemuehler M.J., Narasimhan B. Effect of nanovaccine chemistry on humoral immune response kinetics and maturation. Nanoscale 2014, 6(22):13770-13778.
58. Holmgren J., Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005, 11:S45-S53.
59. Hong S., Bielinska A.U., Mecke A., Keszler B., Beals J.L., Shi X., et al. Interaction of poly(amidoamine) dendrimers with supported lipid bilayers and cells: hole formation and the relation to transport. Bioconjug 2004, 15:774-782.
60. Illum L. Chitosan and its use as a pharmaceutical excipient. Pharm Res 1998, 15:1326-1331.
61. Irache J.M., Salman H.H., Gomez S., Espuelas S., Gamazo C. Poly(anhydride) nanoparticles as adjuvants for mucosal vaccination. Front Biosci (Schol Ed) 2010, 2 S(3):876-890.
62. Jabbal-Gill I. Nasal vaccine innovation. J Drug Target 2010, 18:771-786.
63. Jaganathan K.S., Vyas S.P. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant Hepatitis B antigen administered intranasally. Vaccine 2006, 24:4201-4211.
64. Jahantigh D., Saadati M., Ramandi F., Mousavi M. Novel intranasal vaccine delivery system by Chitosan. J Drug Del Sci Tech 2014, 24(1):33-39.
65. Jain A.K., Goyal A.K., Gupta P.N., Khatri K., Mishra N., Mehta A., et al. Synthesis, characterization and evaluation of novel triblock copolymer based nanoparticles for vaccine delivery against hepatitis B. J Control Release 2009, 136:161-169.
66. Jain A.K., Goyal A.K., Mishra N., Vaidya B., Mangal S., Vyas S.P. PEG-PLA-PEG block copolymeric nanoparticles for oral immunization against hepatitis B. Int J Pharm 2010, 387(1-2):253-262.
67. Jung T., Kamm W., Breitenbach A., Hungerer K.-D., Hundt E., Kissel T. Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice. Pharm Res 2001, 18(3):352-360.
68. Kammona O., Kiparissides C. Recent advances in nanocarrier-based mucosal delivery of biomolecules. J Control Release 2012, 161(3):781-794.
69. Kanchan V., Panda A.K. Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. Biomater 2007, 28(35):5344-5357.
70. Katti D.S., Lakshmi S., Langer R., Laurencin C.T. Toxicity, biodegradation and elimination of polyanhydrides. Adv Drug Deliv Rev 2002, 54:933-961.
71. Kawada J., Wada H., Isobe M., Gnjatic S., Nishikawa H., Jungbluth A.A., et al. Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination. Int J Cancer 2012, 130(3):584-592.
72. Kazzaz J., Neidleman J., Singh M., Ott G., O'Hagan D.T. Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. J Control Release 2000, 67(2-3):347-356.
73. + T-cells in vitro. J Control Release 2013, 168(1):35-40.
74. Kipper M.J., Wilson J.H., Wannemuehler M.J., Narasimhan B. Single dose vaccine based on biodegradable polyanhydride microspheres can modulate immune response mechanism. J Biomed Mater Res A 2006, 76A:798-810.
75. Kiyono H., Fukuyama S. NALT versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol 2004, 4:699-710.
76. Knuschke T., Sokolova V., Rotan O., Wadwa M., Tenbusch M., Hansen W., et al. Immunization with biodegradable nanoparticles efficiently induces cellular immunity and protects against influenza virus infection. J Immunol 2013, 15(12):6221-6229.
77. Kohn J., Langer R. Bioresorbable and bioerodible materials 1996, Biomaterials Academic Press, San Diego.
78. Kong I.G., Sato A., Yuki Y., Nochi T., Takahashi H., Sawada S., et al. Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae. Infect Immun 2013, 81(5):1625-1634.
79. Kumar N., Langer R.S., Domb A.J. Polyanhydrides: an overview. Adv Drug Deliv Rev 2002, 54:889-910.
80. Kumari A., Yadav S.K. Cellular interactions of therapeutically delivered nanoparticles. Expert Opin Drug Deliv 2011, 8:141-151.
81. Kuper C.F., Heer De, Loveren E.V.H., Vos J.G. Handbook of Toxicologic 2002, Academic Press, New York.
82. Lai P., Daear W., Lobenberg R., Prenner E.J. Overview of the preparation of organic polymeric nanoparticles for drug delivery based on gelatine, chitosan, poly(d, l-lactide-co-glycolic acid) and polyalkylcyanoacrylate. Colloids Surf B Biointerfaces 2014, 118C:154-163.
83. Levine M.M. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol 2010, 8:129.
84. Li F., Bae B.C., Na K. Acetylated hyaluronic acid/photosensitizer conjugate for the preparation of nanogels with controllable phototoxicity: synthesis, characterization, autophotoquenching properties, and in vitro phototoxicity against HeLa cells. Bioconjug Chem 2010, 21(7):1312-1320.
85. Li L., Lin S.L., Deng L., Liu Z.G. Potential use of chitosan nanoparticles for oral delivery of DNA vaccine in black seabream Acanthopagrus schlegelii Bleeker to protect from Vibrio parahaemolyticus. J Fish Dis 2013, 36(12):987-995.
86. Li A.V., Moon J.J., Abraham W., Suh H., Elkhader J., Seidman M.A., et al. Generation of Effector Memory T Cell-Based Mucosal and Systemic Immunity with Pulmonary Nanoparticle Vaccination. Sci Transl Med 2013, 5:204ra130.
87. Lin A.Y., Lunsford J., Bear A.S., Young J.K., Eckels P., Luo L., et al. High-density sub-100-nm peptide-gold nanoparticle complexes improve vaccine presentation by dendritic cells in vitro. Nanoscale Res Lett 2013, 8:72.
88. Liu Z., Lv D., Liu S., Gong J., Wang D., Xiong M., et al. Alginic Acid-Coated Chitosan Nanoparticles Loaded with Legumain DNA Vaccine: Effect against Breast Cancer in Mice. PLoS One 2013, 8(4):e60190.
89. Ma T., Wang L., Yang T., Ma G., Wang S. M-cell targeted polymeric lipid nanoparticles containing a toll-like receptor agonist to boost oral immunity. Int J Pharm 2014, 473:296-303.
90. MacDonald T.T. The mucosal immune system. Parasite Immunol 2003, 25:235-246.
91. Mansoor F., Earley B., Cassidy Joseph P., Markey Bryan, et al. Intranasal delivery of nanoparticles encapsulating BPI3V proteins induces an early humoral immune response in mice. Res Vet Sci 2014, 10.1016/j.rvsc.2014.03.002.
92. Maria Teresa De M. Mucosal delivery of vaccine antigens and its advantages in pediatrics. Adv Drug Deliv Rev 2006, 58:52-67.
93. Miller J. Beyond biotechnology: FDA regulation of nanomedicines. Columbia Sci Technol Law Rev 2003, 5:1-29.
94. Mishra N., Goyal A.K., Tiwari S., Paliwal R., Paliwal S.R., Vaidya B., et al. Recent advances in mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymeric carriers. Expert Opin Ther Pat 2010, 20:661-679.
95. Mody K.T., Popat A., Mahony D., Cavallaro A.S., Yu C., Mitter N. Mesoporous silica nanoparticles (MSNs) as antigen carriers and adjuvants for vaccine delivery. Nanoscale 2013, 5:5167-5179.
96. Moffatt S., Cristiano R.J. Uptake characteristics of NGR-coupled stealth PEI/pDNA nanoparticles loaded with PLGA-PEG-PLGA tri-block copolymer for targeted delivery to human monocyte-derived dendritic cells. Int J Pharm 2006, 321:143.
97. Morel S., Didierlaurent A., Bourguignon P., Delhaye S., Baras B., Jacob V., et al. Adjuvant System AS03 containing [alpha]-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011, 29:2461-2473.
98. Mowat A.M., Millington O.R., Chirdo F.G. Anatomical and cellular basis of immunity and tolerance in the intestine. J Pediatr Gastroenterol Nutr 2004, 39:S723-S724.
99. Mowat A.M. Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol 2003, 3:331-341.
100. Mundargi R.C., Babu V.R., Rangaswamy V., Patel P., Aminabhavi T.M. Nano/micro technologies for delivering macromolecular therapeutics using poly(D, L-lactide-co-glycolide) and its derivatives. J Control Release 2008, 125:193-209.
101. Nanda R.K., Hajam I.A., Edao B.M., Ramya K., Rajangam M., Chandra Sekar S., et al. Immunological evaluation of mannosylated chitosan nanoparticles based foot and mouth disease virus DNAvaccine, pVAC FMDV VP1-OmpA in guinea pigs. Biologicals 2014, 10.1016/j.biologicals.2014.01.002.
102. Nazarian S., Gargari S.L., Rasooli I., Hasannia S., Pirooznia N.A. PLGA-encapsulated chimeric protein protects against adherence and toxicity of enterotoxigenic Escherichia coli. Microbiol Res 2014, 169(2-3):205-212.
103. Nelson F.E., Garlapati S., Lai K., Gerdts V., Mutwiri G.K. Polyphosphazenes Enhance Mucosal and Systemic Immune Responses in Mice Immunized Intranasally with Influenza Antigens. Open Vaccine J 2009, 2:134-143.
104. Nelson F.E., Garlapati S., Gerdts V., Babiuk L.A., Mutwiri G.K. PCEP enhances IgA mucosal immune responses in mice following different immunization routes with influenza virus antigens. J Immune Based Ther Vaccin 2010, 8:4. 10.1186/1476-8518-8-4.
105. Nelson F.E., Garlapati S., Gerdts V., Potter A., Babiuk L.A., Mutwiri G.K. Polyphosphazenes The Potential of Polyphosphazenes for Delivery of Vaccine Antigens and Immunotherapeutic Agents. Curr Drug Deliv 2010, 7:13-20.
106. Nils L. Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol 2012, 12:592.
107. Nilsson B., Ekdahl K.N., Mollnes T.E., Lambris J.D. The role of complement in biomaterial-induced inflammation. Mol Immunol 2007, 44:82-94.
108. Ojer P., Neutsch L., Gabor F., Irache J.M., López de Cerain A. Cytotoxicity and cell interaction studies of bioadhesive poly(anhydride) nanoparticles for oral antigen/drug delivery. J Biomed Nanotechnol 2013, 9(11):1891-1903.
109. Oliveira C.R., Rezende C.M., Silva M.R., Pêgo A.P., Borges O., Goes A.M. A New Strategy Based on Smrho Protein Loaded Chitosan Nanoparticles as a Candidate Oral Vaccine against Schistosomiasis. PLoS Negl Trop Dis 2012, 6(11):e1894.
110. Oyewumi M.O., Kumar A., Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines 2010, 9(9):1095-1107.
111. Pawar D., Mangal S., Goswami R., Jaganathan K.S. Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: Effect of mucoadhesive coating on antigen uptake and immune adjuvant activity. Eur J Pharm Biopharm 2013, 3:550-559.
112. Payne L.G., Jenkins S.A., Woods A.L., Grund E.M., Geribo W.E., Loebelenz J.R., et al. Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine. Vaccine 1998, 16(1):92-98.
113. Petersen L.K., Determan A.S., Westgate C., Bendickson L., Nilsen-Hamilton M., Narasimhan B. Lipocalin-2-loaded amphiphilic polyanhydride microparticles accelerate cell migration. J Biomater Sci Polym Ed 2010, 22:1237-1252.
114. Petersen L.K., Sackett C.K., Narasimhan B. A novel, high throughput method to study in vitro protein release from polymer nanospheres. J Comb Chem 2010, 12:51e6.
115. Petersen L.K., Sackett C.K., Narasimhan B. High-throughput analysis of protein stability in polyanhydride nanoparticles. Acta Biomater 2010, 6:3873-3881.
116. Petersen L.K., Ramer-Tait A.E., Broderick S.R., Kong C.S., Ulery B.D., Rajan K., et al. Activation of innate immune responses in a pathogen-mimicking manner by amphiphilic polyanhydride nanoparticle adjuvants. Biomaterials 2011, 32:6815-6822.
117. Petersen L.K., Phanse Y., Ramer-Tait A.E., Wannemuehler M.J., Narasimhan B. Amphiphilic polyanhydride nanoparticles stabilize Bacillus anthracis protective antigen. Mol Pharm 2012, 2(4):874-882.
118. Primard C., Poecheim J., Heuking S., Sublet E., Esmaeili F., Borchard G. Multifunctional PLGA-Based Nanoparticles Encapsulating Simultaneously Hydrophilic Antigen and Hydrophobic Immunomodulator for Mucosal Immunization. Mol Pharm 2013, 10(8):2996-3004.
119. Qing Z., Talton J., Zhang G., Cunningham T., Wang Z., Waters R.C., et al. Large intestine-targeted nanoparticle-releasing oral vaccine to control genitorectal viral infection. Nat Med 2012, 18(8):1291-1296.
120. Rivas E., Gómez-Arnáiz M., Ricoy J.R., Mateos F., Simón R., García-Peñas J.J., et al. Macrophagic myofasciitis in childhood: a controversial entity. Pediatr Neurol 2005, 33:350-356.
121. Rowe R.C., Sheskey P.J., Quinn M.E. Handbook of pharmaceutical excipients 2005, Pharmaceutical Press and American Pharmacist Association, London, United Kingdom.
122. Ruiz-Palacios G.M., Pérez-Schael I., Velázquez F.R., Abate H., Breuer T., Clemens S.C., et al. Human Rotavirus Vaccine Study Group. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354:11-22.
123. Salman H.H., Irache J.M., Gamazo C. Immunoadjuvant capacity of flagellin and mannosamine-coated poly(anhydride) nanoparticles in oral vaccination. Vaccine 2009, 27(35):4784-4790.
124. Sawaengsak C., Mori Y., Yamanishi K., Mitrevej A., Sinchaipanid N. Chitosan nanoparticle encapsulated hemagglutinin-split influenza virus mucosal vaccine. AAPS Pharm Sci Tech 2014, 15(2):317-325.
125. Sharma S., Benson H.A., Mukkur T.K., Rigby P., Chen Y. Preliminary studies on the development of IgA-loaded chitosan-dextran sulphate nanoparticles as a potential nasal delivery system for protein antigens. J Microencapsul 2013, 30(3):283-294.
126. Shim D.H., Ko H.J., Volker G., Potter A.A., Mutwiri G., Babiuk L.A., et al. Efficacy of poly [di(sodium carboxylatophenoxy)phosphazene] (PCPP) as mucosal adjuvant to induce protective immunity against respiratory pathogens. Vaccine 2010, 28(11):2311-2317.
127. Sílvia S.P., Miguel G. Hyaluronic acid and its application in nanomedicine, Carbohydrates Applications in Medicine 2014, 55-89. M.H. Gil (Ed.).
128. Singh J., Pandit S., Bramwell V.W., Alpar H.O. Diphtheria toxoid loaded poly-(epsilon-caprolactone) nanoparticles as mucosal vaccine delivery systems. Methods 2006, 38(2):96-105.
129. Singh M., Briones M., O Hagan DT. A novel bioadhesive intranasal delivery system for inactivated infuenza vaccines. J Control Release 2001, 70:267-276.
130. Slutter B., Hagenaars N., Jiskoot W. Rational design of nasal vaccines. J Drug Target 2008, 16(1):1-17.
131. Slütter B., Soema P.C., Ding Z., Verheul R., Hennink W., Jiskoot W. Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen. J Control Release 2010, 143(2):207-214.
132. Sokolova V., Rotan O., Wadwa M., Knuschke T., Tenbusch M., Hansen W., et al. Immunization with biodegradable nanoparticles efficiently induces cellular immunity and protects against influenza virus infection. J Immunol 2013, 190(12):6221-6229.
133. Stylianou E., Diogo G.R., Pepponi I., van Dolleweerd C., Arias M.A., Locht C., et al. Mucosal delivery of antigen-coated nanoparticles to lungs confers protective immunity against tuberculosis infection in mice. Euro J Immunol 2014, 44(2):440-449.
134. Su X., Fricke J., Kavanagh D.G., Irvine D.J. In vitro and in vivo mRNA delivery using lipid-enveloped pH responsive polymer nanoparticles. Mol Pharm 2011, 6:774-787.
135. Sun R.W., Chen R., Chung N.P., Ho C.M., Lin C.L., Che C.M. Silver nanoparticles fabricated in Herpes buffer exhibit cytoprotective activities toward HIV-1 infected cells. Chem Commun 2005, 40:5059-5061.
136. Tafaghodi M., Sajadi Tabasi S.A., Jaafari M.R. Formulation, characterization and release studies of alginate microspheres encapsulated with tetanus toxoid. J Biomater Sci Polym Ed 2006, 17:909-924.
137. Tafaghodi M., Saluja V., Kersten G.F., Kraan H., Slütter B., Amorij J.P., et al. Hepatitis B surface antigen nanoparticles coated with chitosan and trimethyl chitosan: Impact of formulation on physicochemical and immunological characteristics. Vaccine 2012, 30(36):5341-5348.
138. Teasdale Ian, Brüggemann O. Polyphosphazenes: Multifunctional, Biodegradable Vehicles for Drug and Gene Delivery. Polymers 2013, 5:161-187.
139. Thejani E.R., Mary Stover-H., Xiomara F., Holly A.E., David DLo Claudin 4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted delivery. J Control Release 2010, 142(2):196-205.
140. Tiyaboonchai W. Chitosan Nanoparticles: A Promising System for Drug Delivery. Naresuan University J 2003, 11(3):51-66.
141. Tongtong Maa, Wangb Lianyan, Yang Tingyuan, Ma Guanghui, Wang Siling Homogeneous PLGA-Lipid Nanoparticle as a Promising Oral Vaccine Delivery System for Ovalbumin. Asian J Pharml Sci 2014, 10.1016/j.ajps.2014.03.002.
142. Ulery B.D., Kumar D., Ramer-Tait A.E., Metzger D.W., Wannemuehler M.J., Narasimhan B. Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases. PLoS One 2011, 6:e17642.
143. US 7947309 B2 Application number US 12/590,548; Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants May 24, 2011.
144. US WO2014120804 A1 Application number PCT/US2014/013647 "Enteric coated nanoparticles for oral vaccine and drug delivery and methods of production and use thereof" Janaurary 2014.
145. Verheula R.J., Slütterb B., Balb S.M., Bouwstrab J.A., Jiskootb W., Hennink W.E. Covalently stabilized trimethyl chitosan-hyaluronic acid nanoparticles for nasal and intradermal vaccination. J Control Release 2011, 156(1):46-52.
146. Verma A., Mittal A., Gupta A. Development and characterization of bipolymer based nanoparticulate carrier system as vaccine adjuvant for effective immunization. Int J Pharmacy Pharma Sci 2013, 5(2):188-195.
147. Vicente S., Peleteiro M., Díaz-Freitas B., Sanchez A., González-Fernández Á., Alonso M.J. Co-delivery of viral proteins and a TLR7 agonist from polysaccharide nanocapsules: a needle-free vaccination strategy. J Control Release 2013, 172(3):773-781.
148. Vimal S., Abdul Majeed K.S.N., Madana MA Nambi N., Farooka C., Venkatesana G., Tajua S., et al. Delivery of DNA vaccine using chitosan-tripolyphosphate (CS/TPP) nanoparticles in Asian sea bass, Lates calcarifer (Bloch, 1790) for protection against nodavirus infection. Aquaculture 2014, 420-421:240-246.
149. Wendorf J., Singh M., Chesko J., Kazzaz J., Soewanan E., Ugozzoli M., et al. A practical approach to the use of nanoparticles for vaccine delivery. J Pharmacol Sci 2006, 95:2738-2750.
150. Wolf B.W., Garleb K.A., Choe Y.S., Humphrey P.M., Maki K.C. Pullulan is a slowly digested carbohydrate in humans. J Nutr 2003, 133:1051-1055.
151. Wright P.F., Kozlowski P.A., Rybczyk G.K., Goepfert P., Staats H.F., VanCott T.C., et al. Detection of mucosal antibodies in HIV type1-infected individuals. AIDS Res Hum Retroviruses 2002, 18:1291-1300.
152. Wright P.F. Inductive/Effector Mechanisms for Humoral Immunity at Mucosal Sites. Am J Reprod Immunol 2011, 65:248-252.
153. Xiang S.D., Scholzen A., Minigo G., David C., Apostolopoulos V., Mottram P.L., et al. Pathogen recognition and development of particulate vaccines: does size matter?. Methods 2006, 40(1):1-9.
154. Yan Z., Wang J.B., Gong S.S., Huang X. Cell proliferation in the endolymphatic sac in situ after the rat Waldeyer ring equivalent immuno-stimulation. Laryngoscope 2003, 113:1609-1614.
155. Yao W., Peng Y., Du M., Luo J., Zong L. Preventative vaccine-loaded mannosylated chitosan nanoparticles intended for nasal mucosal delivery enhance immune responses and potent tumor immunity. Mol Pharm 2013, 10(8):2904-2914.
156. Zhao K., Zhang Y., Zhang X., Shi C., Wang X., Wang X., et al. Chitosan-coated poly(lactic-co-glycolic) acid nanoparticles as an efficient delivery system for Newcastle disease virus DNA vaccine. Int J Nanomedicine 2014, 9:4609-4619.
157. Zhao L., Seth A., Wibowa N., Zhao C., Zhaoa C.X., Mitter N., et al. Nanoparticle vaccines. Vaccine 2014, 32:327-337.
158. Zolnik B.S., González-Fernández A., Sadrieh N., Dobrovolskaia M.A. Minireview: nanoparticles and the immune system. Endocrinology 2010, 151:458-465.